ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2025

Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity-matched cohort study.

Sophie L Preuß et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.